January's IPO market finished up with the introduction of six new companies to public trading markets. The IPO week kicked off with the first of three biotechs, Annovis Bio, Inc. (NYSE: ANVS) pricing on January 29 to trade on the New York Stock Exchange. The Phase 2 biotech which develops therapies for neurodegenerative diseases, raised $12 million by offering 2 million shares at $6, the lowest range of its estimated pricing. The company has a market capitalization of $42 million, which was also below the IPO's market expectations.
Anpac Bio-Medical Therapeutics, Inc. (NASDAQ: ANPC) was next to price last week, issuing its stock on the global Nasdaq on January 30. The Chinese diagnostics company also priced its IPO at the lower end by raising over $16 million from 1.3 million offered shares at $12 per share.
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) also priced on January 30, raising $201,140,004 from offering 10,586,316 shares priced on the stock's higher end at $19 per share. The company is a Phase 1-ready biotech that develops targeted kinase inhibitors for solid tumors.
1Life HealthCare (NASDAQ: ONEM), also referred to as One Medical, set its share price to trade on the global Nasdaq on January 31. The health clinic brand raised $262.5 million by offering 17.5 million shares prices in stock's midrange of $15.
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) joined also the global Nasdaq on January 31. The Phase 3 biotech who develops topical therapies for common skin diseases had raised over $159 million from offering about 9.4 million shares set on the stock's higher price range of $17 per share.
To cap off last week, Reynolds Consumer Products, Inc. (NASDAQ: REYN) has raised over $1.2 billion from offering over 41.1 million public shares priced at $26 per share. The leading provider of consumer household products listed on the global Nasdaq on January 31.
IPOs scheduled to price this week:
Beam Therapeutics, Inc is poised to price on the global Nasdaq on February 6. The preclinical, gene editing biotech plans to offer $122, 187,500 from 6.25 million shares price between $15-$17 per share. Beam is expected to begin a new wave of Investigational New Drug (IND) filings for 2020.
Casper Sleep Inc. is set to trade on the New York Stock Exchange on February 6. The highly anticipated tech-enabled mattress company expects to raise over $182 million in offering 8.35 million shares priced in the range of $17-$19 per share. The company is widely criticized as being unprofitable despite its rapid growth.
PPD, Inc. will also begin trading on the global Nasdaq on February 6. The contract research organization is returning to public trading markets by aiming to raise over $1.8 billion from 60 million offered shares priced between $24-$27 per share. The IPO proceeds are set to be used to pay down the company's debt.
Schrodinger, Inc. is the last company slated to join the global Nasdaq on February 6. The provider of life science and materials research software plans to raise $184 million from offering 10 million shares priced in the range of $14-$16 per share.
NexPoint Real Estate Finance, Inc. plans to issue on the New York Stock Exchange on February 7. The mortgage real estate investment trust (REIT) aims to raise over $120 million from 5 million shares priced between $19-$21 per share.
OneWater Marine, Inc. is also scheduled to price on the New York Stock Exchange on February 7. The recreational boat retailer has made 17 acquisition since the company's formation in 2014. The company estimates that it will raise over $74 million from about 4.6 million shares priced at $12-$14 per share.
Professional Holding Corp. is that last IPO set to issue on the global Nasdaq on February 7. The community bank from South Florida is planning to raise over $74.8 million from offering 3.1 million shares priced in the range of $19-$21 per share.